Back to search

Peptide record

TPDB41358

H-14 Anticancer standard
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41358
H-14
Anticancer
Cancer-related peptides
CancerPPD 2.0 Peptipedia dbACP pep-lab
standard
No
A 29-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, Peptipedia, dbACP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
IKLSKKTKKNLKKVLKGAIKGAIAVAKMV-NH2
Physicochemical Analysis
C143H268N40O33S1
RDCEQHFPWY
K
3108.01
11.46
10
0
14
+10
7.30
0.062
124.48
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
0
0.00
3
Residue Composition
number
4
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
3
I
3
L
10
K
1
M
0
F
0
P
1
S
1
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 10 M: 1 F: 0 P: 0 S: 1 T: 1 W: 0 Y: 0 V: 3
Chemical Descriptors
29
C143H268N40O33S1
3108.01
11.46
+10
7.30
0.062
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.98 ± 0.11 µM
Anticancer
0.98

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 1.841 ± 0.34 µM
Anticancer
1.841

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 3 Activity

Activity

IC50
IC50 = 4.54 ± 0.25 µM
Anticancer
4.54

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019